CEVYX
Price
$13.88
Change
+$0.08 (+0.58%)
Updated
Sep 11 closing price
Net Assets
912.15M
TEDIX
Price
$33.07
Change
+$0.15 (+0.46%)
Updated
Sep 11 closing price
Net Assets
9.31B
Interact to see
Advertisement

CEVYX vs TEDIX

CEVYX vs TEDIX Comparison Chart in %
View a ticker or compare two or three
VS
CEVYX vs. TEDIX commentary
Sep 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CEVYX is a StrongBuy and TEDIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TEDIX has more cash in the bank: 9.31B vs. CEVYX (912M). CEVYX pays higher dividends than TEDIX: CEVYX (3.40) vs TEDIX (1.50). CEVYX was incepted earlier than TEDIX: CEVYX (14 years) vs TEDIX (34 years). TEDIX (1.20) is less costly to investors than CEVYX (0.77). CEVYX is a more actively managed with annual turnover of: 63.00 vs. TEDIX (42.28). TEDIX has a lower initial minimum investment than CEVYX: TEDIX (1000) vs CEVYX (1000000). CEVYX annual gain was more profitable for investors over the last year : 7.49 vs. TEDIX (2.26). CEVYX return over 5 years is better than : 22.34 vs. TEDIX (9.28).
CEVYXTEDIXCEVYX / TEDIX
Total Expense Ratio0.771.2064%
Annual Report Gross Expense Ratio0.771.2064%
Fund Existence14 years34 years-
Gain YTD11.5256.953166%
Front LoadN/A6%-
Min. Initial Investment10000001000100,000%
Min. Initial Investment IRAN/AN/A-
Net Assets912M9.31B10%
Annual Yield % from dividends3.401.50226%
Returns for 1 year7.492.26331%
Returns for 3 years34.2816.85203%
Returns for 5 years22.349.28241%
Returns for 10 years52.2422.47232%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BFONX20.860.19
+0.92%
Biondo Focus Investor
JAMCX33.800.27
+0.81%
JPMorgan Mid Cap Value A
BUFTX18.050.14
+0.78%
Buffalo Mid Cap Discovery
MSFBX26.910.18
+0.67%
Morgan Stanley Inst Global Franchise A
FBTCX36.63-0.01
-0.03%
Fidelity Advisor Biotechnology C